Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.490
-0.120 (-2.60%)
At close: Mar 13, 2026, 4:00 PM EDT
4.460
-0.030 (-0.67%)
After-hours: Mar 13, 2026, 5:44 PM EDT

Taysha Gene Therapies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
6.318.3315.452.5--
Revenue Growth (YoY)
-36.36%-46.07%517.55%---
Gross Profit
6.318.3315.452.5--
Selling, General & Admin
31.6628.9530.0537.3641.3211.11
Research & Development
76.786656.7891.17131.9431.89
Other Operating Expenses
-4.841.0736.42--
Total Operating Expenses
108.4499.7987.89164.95173.2743
Operating Income
-102.13-91.46-72.44-162.45-173.27-43
Interest Income
8.056.943.570.250.170.05
Interest Expense
-0.07-0.1-5-3.8-1.43-0.03
Other Non-Operating Income (Expense)
-5.78-4.68-37.7-0.02--17.03
Total Non-Operating Income (Expense)
2.22.16-39.13-3.57-1.26-17.01
Pretax Income
-99.93-89.3-111.57-166.01-174.52-60.01
Net Income
-99.93-89.3-111.57-166.01-174.52-60.01
Net Income to Common
-99.93-89.3-111.57-166.01-174.52-60.01
Shares Outstanding (Basic)
297250116443818
Shares Outstanding (Diluted)
297250116443818
Shares Change (YoY)
26.15%115.41%164.20%16.74%113.13%-
EPS (Basic)
-0.33-0.36-0.96-3.78-4.64-3.40
EPS (Diluted)
-0.33-0.36-0.96-3.78-4.64-3.40
Free Cash Flow
-85.16-81.6-76.89-109.01-132.35-30.81
Free Cash Flow Per Share
-0.29-0.33-0.66-2.48-3.52-1.74
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-1618.54%-1097.55%-468.83%-6492.69%--
Profit Margin
-1583.66%-1071.62%-722.06%-6635.25%--
FCF Margin
-1349.64%-979.23%-497.62%-4356.87%--
EBITDA
-100.98-90.21-71.07-161.28-172.78-42.99
EBITDA Margin
-1600.32%-1082.61%-459.96%-6445.84%--
EBIT
-102.13-91.46-72.44-162.45-173.27-43
EBIT Margin
-1618.54%-1097.55%-468.83%-6492.69%--
Updated Nov 4, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q